Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY April 2019 Price Cut Wouldn’t Fit the Purpose of Tax Tweak: MHLW Insurance Chief
August 31, 2018
-
BUSINESS With Bullish Maviret, AbbVie Aims for Double-Digit Growth to Join Top 20 in 2018
August 30, 2018
-
BUSINESS Imfinzi, Gazyva Now Available in Japan
August 30, 2018
-
REGULATORY MHLW Discussing Use of Data from “Specified Clinical Research” in Application Dossiers, Will Issue Preliminary Conclusions by March
August 29, 2018
-
BUSINESS Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
August 28, 2018
-
BUSINESS Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
-
REGULATORY Japan Eyes State Funds to Boost Sakigake Review Staffers: FY2019 Budget Request
August 27, 2018
-
REGULATORY MHLW to Expand MID-NET and Coordinate with Other Databases and Registries to Improve Safety Measures: Official
August 27, 2018
-
ORGANIZATION Regulatory Science Society Says “No” to Off-Label Info Supply by Drug Reps Conditionally OK’ed in Draft MHLW GLs
August 24, 2018
-
REGULATORY Chuikyo Discusses ICER Evaluations for Drugs with Multiple Indications
August 23, 2018
-
REGULATORY Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
August 22, 2018
-
BUSINESS Mitsubishi Tanabe Going Digital to Shed Drug Discovery and Sales Outlays: President
August 21, 2018
-
BUSINESS I/O in Lung Cancer - 2: After MYSTIC Flop, AstraZeneca’s Imfinzi Makes Comeback with Stage III NSCLC Nod
August 20, 2018
-
REGULATORY MHLW Revving Up Biosimilar Drive with Educational Workshop for Healthcare Pros
August 17, 2018
-
REGULATORY Japan Approves Nesp “Biosame,” Eyes Riveted on December Listing
August 16, 2018
-
BUSINESS I/O in Lung Cancer - 1: US Merck Sweeping Frontline NSCLC Space with Keytruda
August 10, 2018
-
BUSINESS As Rituxan Biosimilar Enjoys Solid Start, Sandoz Japan Chief Says It’s Important to Be First to Market
August 9, 2018
-
BUSINESS Otsuka’s Half-Year Pharma Sales Up 4.1% on Global Brands
August 9, 2018
-
TRENDS Strong April-June Sales Show Market Shift to SGLT2/DPP-4 Combos
August 8, 2018
-
BUSINESS Sumitomo Dainippon Chief Rules Out Divestment of Cash-Cow LLPs
August 8, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…